Want to Participate in a Clinical Research Trial for Depression?
Fill out this quick Pre-Screening Questionnaire
- Please complete this form to determine your eligibility for our Depression studies
Pre-screening questionnaire and your privacy
Your privacy and confidentiality are our top priorities at Excell Research. By completing the study pre-screening questionnaire, you may be asked to provide personal details such as age, gender, and current medical condition. Rest assured, this information is solely used to assess your eligibility for our ongoing studies at our Oceanside, CA location.
Should you qualify, one of our staff members will reach out to conduct a phone-screening session. Please note that your personal information will be handled with the utmost care and will only be shared with relevant personnel involved in the clinical research study process.
We guarantee that your information will not be sold to third-party companies, and it will not be stored or collected without your explicit consent. Your trust is invaluable to us, and we are committed to maintaining the highest standards of privacy protection throughout your participation in our research studies. Thank you for considering Excell Research.
Many pharmaceutical companies and Excell Research are conducting these studies under the Food and Drug Administration (FDA) to learn more about new investigational drugs or treatments. Read our privacy policy to learn more about how your information will be kept private.
Depression Clinical Research Studies Available
Depression Clinical Research Studies
Sponsor:
Alto Neuroscience
Protocol Number:
ALTO-100-201
Summary: The ALTO-100-201 study is evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential study visits.
Eligibility Criteria
Key Inclusion Criteria:
- Symptoms of depression for at least 6 weeks prior to entering the study.
- Willing to comply with all study assessments and procedures.
- Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
- Primary symptoms of post-traumatic stress disorder.
- Clinically significant medical conditions.
- History of substance abuse in the past 3 months.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-70
Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table
Sponsor Website: https://www.altoneuroscience.com/
Other Clinical Research Trials Available to Participants
Join the forefront of scientific advancement by participating in Excell’s clinical trial studies. Your contribution could lead to groundbreaking treatments for prevalent and challenging diseases and conditions.
At Excell, we prioritize providing transparent and thorough information about the risks and benefits of participation. You’ll receive clear answers to all your inquiries, empowering you to make informed decisions about your health.
Additionally, financial compensation may be available for eligible participants who complete visits for our clinical trial studies.
Take the first step towards making a difference in medical research. Sign up for our clinical trial studies today and play a vital role in shaping the future of healthcare.
Generalized Anxiety Clinical Research Studies
Sponsor:
Sunovion Pharmaceuticals
Protocol Number:
SEP361-226
Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of SEP361 n adults with Generalized Anixety Disorder.
Eligibility Criteria:
Key Inclusion Criteria:
- Male or female subject between 18 to 65 years of age.
- Symptoms of Generalized Anxiety Disorder over the past 6 months.
- Primary focus of treatment is Generalized Anxiety Disorder.
Key Exclusion Criteria:
- Diagnosis other than Generalized Anxiety Disorder that was the primary focus of treatment within 12 months before Screening.
- Previous inadequate response to more than 3 antidepressant treatments.
- Any clinically significant unstable medical condition or any clinically significant chronic disease, that would limit the subject’s ability to complete and/or participate in the study.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18 to 65
Clinicaltrials.gov Link:
https://clinicaltrials.gov/study/NCT05729373?term=SEP361-226&aggFilters=status:rec&rank=1&tab=table
Sponsor Website:
Schizophrenia Clinical Research Studies
Sponsor:
Neurocrine
Study Name:
Erudite Study
Protocol Number:
NBI-1065844-CIAS2023
Summary: The Erudite study is evaluating the safety, efficacy, and tolerability of Luvadaxistat in subjects with cognitive impairment associated with schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
- Experiencing cognitive impairment with a previous diagnosis of Schizophrenia.
- Willing to comply with all study assessments and procedures.
- Currently taking an antipsychotic medication for at least 3 weeks prior to study entry at a 2-6mg Risperidone equivalent.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
- Current substance/alcohol abuse.
- Clinically significant medical conditions.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-50
Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05182476?term=NBI-1065844-CIAS2023&draw=2&rank=1
Sponsor Website: https://www.neurocrine.com/
OCD Clinical Research Studies
Sponsor:
Biohaven Pharmaceuticals
Study Name:
Biohaven Study
Protocol Number:
BHV4157-302
Summary: The Biohaven study is a placebo-controlled study evaluating the safety and efficacy of Troriluzole n adults taking an SSRI to treat symptoms of obsessive-compulsive disorder.
Eligibility Criteria:
Key Inclusion Criteria:
- Experiencing moderate to severe symptoms of obsessive-compulsive disorder in the past year.
- Currently taking an SSRI medication for 8 weeks prior to study entry. (Zoloft, Prozac, Lexapro, Celexa, ect.)
- Willing to stop exclusionary psychiatric medications prior to study entry.
Key Exclusion Criteria:
- Lifetime history of bi-polar disorder, schizophrenia, borderline personality disorder or autism spectrum disorders.
- Unwilling to discontinue exclusionary medications or comply with study procedures.
- Any clinically significant unstable medical condition or any clinically significant chronic disease.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18 to 65
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT04641143?term=BHV4157-302&draw=2&rank=1
Sponsor Website:
Adolescent Migraine Clinical Research Studies
Sponsor:
AbbVie
Name:
Periscope Study
Protocol Number:
3110-305-002
Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Ubrogepant in acute treatment of migraine with or without aura in children and adolescents.
Eligibility Criteria
Key Inclusion Criteria:
- History of 1 to 14 migraine attacks per month with moderate to severe headaches in each of the 2 months prior to study entry.
- Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine.
Key Exclusion Criteria:
- Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular, or neurologic disease.
- Other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
12-17
Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/study/NCT05125302?term=3110-305-002&draw=2&rank=2
Resources for Depression
Depression
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Also called major depressive disorder or clinical depression, it affects how you feel, think and behave and can lead to a variety of emotional and physical problems. You may have trouble doing normal day-to-day activities, and sometimes you may feel as if life isn’t worth living.
Symptoms
Although depression may occur only once during your life, people typically have multiple episodes. During these episodes, symptoms occur most of the day, nearly every day and may include:
- Feelings of sadness, tearfulness, emptiness or hopelessness
- Angry outbursts, irritability or frustration, even over small matters
- Loss of interest or pleasure in most or all normal activities, such as sex, hobbies or sports
- Sleep disturbances, including insomnia or sleeping too much
- Tiredness and lack of energy, so even small tasks take extra effort
- Reduced appetite and weight loss or increased cravings for food and weight gain
- Anxiety, agitation or restlessness
- Slowed thinking, speaking or body movements
- Feelings of worthlessness or guilt, fixating on past failures or self-blame
- Trouble thinking, concentrating, making decisions and remembering things
- Frequent or recurrent thoughts of death, suicidal thoughts, suicide attempts or suicide
- Unexplained physical problems, such as back pain or headaches
